原発性肺癌におけるCA 19‐9の意義  血中濃度と組織内局在の検討:血中濃度と組織内局在の検討  [in Japanese] The carbohydrate antigen 19-9 in serum and tissue of patients with lung cancer.  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

原発性肺癌患者56例の血清CA19-9濃度を測定した. 初診時・治療前の陽性率は16%, 経過中最高値をとっても30%とCEAにくらべ低かった. 血清濃度は腺癌とくに気管支腺型腺癌で著増し, 免疫組織化学的にも大量のCA19-9の局在が認められた. しかし, 血清濃度と組織内局在とは必ずしも相関せず, 腫瘍の大きさや血管浸潤などが関与しているものと思われた.

The 19-9 monoclonal antibody, prepared by Koprowski et al., reacts with a carbohydrate antigenic determinant (CA 19-9) which has been identified as a sialylated lacto-Nfucopentaose II. CA19-9 has been known to be a useful tumor marker for gastrointestinal carcinoma, especially pancreatic cancer.<BR>The authors investigated the significance of this antigen for lung cancer. We measured serum CA 19-9 concentration in 56 patients with lung cancer by a forward sandwich type radioimmunometric assay (cut-off value 37 U/ml), and immunostained the antigen in 32 lung cancer tissue by an immunoperoxidase assay.<BR>The positive rate of serum CA 19-9 concentration was 16%, lower than that of carcinoembryonic antigen (CEA). The concentration of the antigen was markedly increased in patients with bronchial gland type adenocarcinoma, and strongly stained in cancer tissue.

Journal

  • Haigan

    Haigan 28(1), 11-17, 1988

    The Japan Lung Cancer Society

Cited by:  11

Codes

  • NII Article ID (NAID)
    110003131846
  • NII NACSIS-CAT ID (NCID)
    AN00203978
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    0386-9628
  • Data Source
    CJPref  NII-ELS  IR  J-STAGE 
Page Top